Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndrome.
A case is reported of idiopathic relapsed autoimmune hemolytic anemia successfully treated with rituximab. A 43-year-old white male patient with past medical history of Evans syndrome was found to have recurrent autoimmune hemolytic anemia. Previous treatments included steroids, splenectomy, intravenous immunoglobulin, plasmapheresis, staphylococcal Protein A immunoadsorption (Prosorba column), and chemotherapeutic agents (cytoxan and vincristine). Rituximab was given weekly at 375 mg/m2 for 4 doses. The drug was well tolerated and the patient remains in remission 9 months after completion of therapy.
Galor
Anat
A
MetroHealth Medical Center, CWRU School of Medicine, Cleveland, Ohio 44109-1998, USA.
O'Brien
Timothy
T
D000328:Adult; D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D012008:Recurrence; D012074:Remission Induction; D019233:Retreatment; D000069283:Rituximab; D013577:Syndrome; D013921:Thrombocytopenia / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab